Risk Stratification and Prognostic Factors in the Post-Myocardial Infarction Patient

American Journal of Cardiology

Volumn 102, Issue 5 SUPPL., 2008, Pages 13G-20G

  Cannon, Christopher P ^a   Greenberg, Barry H ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; MEVINOLIN; NEUROHORMONE; ORBOFIBAN; PRAVASTATIN; SIMVASTATIN; TIROFIBAN; TROPONIN; VALSARTAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EMERGENCY WARD; FIBRINOLYSIS; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEMODYNAMIC STRESS; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MEDICAL DECISION MAKING; MORTALITY; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

EID: 50949089643     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.06.006     Document Type: Article

References (53)

1. Cannon C.P., and O'Gara P.T. Critical Pathways in Cardiovascular Medicine. 2nd ed. (2007), Lippincott Williams & Wilkins, Philadelphia 131
2. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey Jr. D.E., Chavey WE I.I., Fesmire F.M., Hochman J.S., Levin T.N., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction). Circulation 116 (2007) 803-877
3. Antman E.M., Cohen M., Bernink P.J., McCabe C.H., Horacek T., Papuchis G., Mautner B., Corbalan R., Radley D., and Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284 (2000) 835-842
4. Boersma E., Pieper K.S., Steyerberg E.W., Wilcox R.G., Chang W.C., Lee K.L., Akkerhuis K.M., Harrington R.A., Deckers J.W., Armstrong P.W., et al., PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 101 (2000) 2557-2567
5. Califf R.M., Pieper K.S., Lee K.L., Van De Werf F., Simes R.J., Armstrong P.W., and Topol E.J. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 101 (2000) 2231-2238
6. Jacobs Jr. D.R., Kroenke C., Crow R., Deshpande M., Gu D.F., Gatewood L., and Blackburn H. PREDICT: a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina. The Minnesota Heart Survey. Circulation 100 (1999) 599-607
7. Krumholz H.M., Chen J., Chen Y.T., Wang Y., and Radford M.J. Predicting one-year mortality among elderly survivors of hospitalization for an acute myocardial infarction: results from the Cooperative Cardiovascular Project. J Am Coll Cardiol 38 (2001) 453-459
8. Morrow D.A., Antman E.M., Charlesworth A., Cairns R., Murphy S.A., de Lemos J.A., Giugliano R.P., McCabe C.H., and Braunwald E. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation. An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102 (2000) 2031-2037
9. Morrow D.A., Antman E.M., Giugliano R.P., Cairns R., Charlesworth A., Murphy S.A., de Lemos J.A., McCabe C.H., and Braunwald E. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 358 (2001) 1571-1575
10. Cannon C.P. Acute coronary syndromes: risk stratification and initial management. Cardiol Clin 23 (2005) 401-409
11. O'Connor C.M., Hathaway W.R., Bates E.R., Leimberger J.D., Sigmon K.N., Kereiakes D.J., George B.S., Samaha J.K., Abbottsmith C.W., Candela R.J., Topol E.J., and Califf R.M. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. Am Heart J 133 (1997) 663-673
12. Ali A.S., Rybicki B.A., Alam M., Wulbrecht N., Richer-Cornish K., Khaja F., Sabbah H.N., and Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J 138 (1999) 1133-1139
13. Steg P.G., Dabbous O.H., Feldman L.J., Cohen-Solal A., Aumont M.C., López-Sendón J., Budaj A., Goldberg R.J., Klein W., Anderson Jr. F.A., and Global Registry of Acute Coronary Events Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromesobservations from the Global Registry of Acute Coronary Events (GRACE). Circulation 109 (2004) 494-499
14. Velazquez E.J., Francis G.S., Armstrong P.W., Aylward P.E., Diaz R., O'Connor C.M., White H.D., Henis M., Rittenhouse L.M., Kilaru R., et al., VALIANT registry. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J 25 (2004) 1911-1919
15. Setoguchi S., Stevenson L.W., and Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 154 (2007) 260-266
16. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article. J Am Coll Cardiol 46 (2005) 1116-1143
17. Tang W.H., Francis G.S., Morrow D.A., Newby L.K., Cannon C.P., Jesse R.L., Storrow A.B., Christenson R.H., Apple F.S., Ravkilde J., Wu A.H., and National Academy of Clinical Biochemistry Laboratory Medicine. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure (NACB). Circulation 116 (2007) 1-11
18. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 (1994) 311-322
19. De Luca G., Suryapranata H., Ottervanger J.P., and Antman E.M. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 109 (2004) 1223-1225
20. Cannon C.P., Gibson C.M., Lambrew C.T., Shoultz D.A., Levy D., French W.J., Gore J.M., Weaver W.D., Rogers W.J., and Tiefenbrunn A.J. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 283 (2000) 2941-2947
21. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M., and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
22. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113 (2006) 2335-2362
23. Morrow D.A., Cannon C.P., Rifai N., Frey M.J., Vicari R., Lakkis N., Robertson D.H., Hille D.A., DeLucca P.T., DiBattiste P.M., et al., TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 286 (2001) 2405-2412
24. Donahoe S.M., Stewart G.C., McCabe C.H., Mohanavelu S., Murphy S.A., Cannon C.P., and Antman E.M. Diabetes and mortality following acute coronary syndromes. JAMA 298 (2007) 765-775
25. Crilley J.G., and Farrer M. Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Heart 86 (2001) 638-642
26. Bettencourt Ferreira A., Pardal-Oliveira N., Pereira M., Queirós C., Araújo V., Cerqueira-Gomes M., and Maciel M.J. Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction. Clin Cardiol 23 (2000) 921-927
27. Choy A.M., Darbar D., Lang C.C., Pringle T.H., McNeill G.P., Kennedy N.S., and Struthers A.D. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 72 (1994) 16-22
28. de Lemos J.A., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., Hall C., Cannon C.P., and Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
29. Lindahl B., Lindbäck J., Jernberg T., Johnston N., Stridsberg M., Venge P., and Wallentin L. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 45 (2005) 533-541
30. Morrow D.A., de Lemos J.A., Sabatine M.S., Murphy S.A., Demopoulos L.A., DiBattiste P.M., McCabe C.H., Gibson C.M., Cannon C.P., and Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (2003) 1264-1272
31. Sabatine M.S., Morrow D.A., de Lemos J.A., Gibson C.M., Murphy S.A., Rifai N., McCabe C., Antman E.M., Cannon C.P., and Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
32. Kou V., and Nassisi D. Unstable angina and non-ST-segment myocardial infarction: an evidence-based approach to management. Mt Sinai J Med 73 (2006) 449-468
33. Rozenman Y., and Gotsman M.S. The earliest diagnosis of acute myocardial infarction. Annu Rev Med 45 (1994) 31-44
34. Newby L.K., Goldmann B.U., and Ohman E.M. Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 41 (2003) 31S-36S
35. Heeschen C., Hamm C.W., Goldmann B., Deu A., Langenbrink L., White H.D., and PRISM Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban: Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 354 (1999) 1757-1762
36. Morrow D.A., Antman E.M., Tanasijevic M., Rifai N., de Lemos J.A., McCabe C.H., Cannon C.P., and Braunwald E. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 36 (2000) 1812-1817
37. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., Gotto Jr. A.M., and Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
38. Ridker P.M., and JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108 (2003) 2292-2297
39. Køber L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D.S., Auclert L., Pauly N.C., and Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
40. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
41. Packer M., Fowler M.B., Roecker E.B., Coats A.J., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Staiger C., et al., Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
42. Richards A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., Buttimore R.C., Lainchbury J.G., Elliott J.M., Ikram H., Crozier I.G., and Smyth D.W. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 (1998) 1921-1929
43. Richards A.M., Crozier I.G., Yandle T.G., Espiner E.A., Ikram H., and Nicholls M.G. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 69 (1993) 414-417
44. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
45. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337 (1997) 1360-1369
46. Ridker P.M., Morrow D.A., Rose L.M., Rifai N., Cannon C.P., and Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45 (2005) 1644-1648
47. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E., and Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
48. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
49. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
50. Morrow D.A., de Lemos J.A., Sabatine M.S., Wiviott S.D., Blazing M.A., Shui A., Rifai N., Califf R.M., and Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114 (2006) 281-288
51. Ray K.K., Cannon C.P., Cairns R., Morrow D.A., Rifai N., Kirtane A.J., McCabe C.H., Skene A.M., Gibson C.M., Ridker P.M., Braunwald E., and PROVE IT-TIMI 22 Investigators. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1417-1424
52. Wylie J.V., Murphy S.A., Morrow D.A., de Lemos J.A., Antman E.M., and Cannon C.P. Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. Am Heart J 148 (2004) 173-180
53. Morrow D.A., and Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 108 (2003) 250-252